Brief: Tonix Pharmaceuticals Announces Submission Of The TNX-102 Sl New Drug Application (NDA) For Fibromyalgia To The U.S. Food And Drug Administration (FDA)
16/10/2024 13:01
Oct 16 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS ANNOUNCES SUBMISSION OF THE TNX-102
SL NEW
DRUG APPLICATION (NDA) FOR FIBROMYALGIA TO THE U.S. FOOD AND
DRUG ADMINISTRATION (FDA)
* TONIX PHARMACEUTICALS HOLDING CORP - FDA DECISION ON
TNX-102 SL
EXPECTED IN 2025
Source text for Eikon: ID:nGNX2Pxxbx
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview